@article{ref1,
title="Tamoxifen and potent CYP2D6 inhibitors: A potentially lethal interaction",
journal="Irish medical journal",
year="2015",
author="Battley, J.E. and Oconnor, M. and Barron, T.I. and O'reilly, S.",
volume="108",
number="6",
pages="e1-e1",
abstract="Sir Tamoxifen has a well-established role in the management of oestrogen-receptor positive breast cancer halving the 5-year recurrence risk of early stage breast cancer, reducing mortality and controlling metastasis. It is an inactive pro-drug which is activated by the hepatic cytochrome P450 system. © 2015, Irish Medical Association. All rights reserved.<p /><p>Language: en</p>",
language="en",
issn="0332-3102",
doi="",
url="http://dx.doi.org/"
}